



Iowa Department of Human Services

Terry E. Branstad
Governor

Kim Reynolds
Lt. Governor

Charles M. Palmer
Director

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

April 1, 2015

**Location: Fred Maytag II Scout Center
Conference Rooms 2 & 3
6123 Scout Trail
Des Moines, Iowa 50321**

Time: 9:30 a.m. – 1:30 p.m.

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
 - b) Approval of the Minutes
2. Medicaid Modernization Presentation
3. Complex Pharmaceutical Oversight Program (CPOP) – Tina Valentino, Pharm.D.
4. Commission Business
 - a) DHS Recommendation Letter – February 2015
5. IME Updates
6. Prevalence Report Summary
7. Case Studies
8. Public Comment (See Conflict of Interest Disclosure Form)
9. ProDUR Edits
 - a) Impact of Select CNS Stimulant Quantity Limits
10. Focus Studies/Provider Education Initiatives
 - a) Naltrexone Utilization in the Pediatric Population – Follow Up
 - b) Adalimumab use without Methotrexate – Follow Up
 - c) Duplicate Beta-Blockers – Initial Review
 - d) Vimpat Dosing – Initial Review
11. Public Comment (See Conflict of Interest Disclosure Form)
12. Prior Authorization
 - a) Hepatitis C Agents – Initial Review

- b) CNS Stimulants & Atomoxetine – Initial Review
- c) Dextromethorphan/Quinidine (Nuedexta) – Initial Review
- d) Chronic Pain Syndromes – Initial Review
- e) Sedative/Hypnotics – Non-Benzodiazepine – Initial Review
- f) Apixaban (Eliquis) – Second Review
- g) Thrombopoietin Receptor Agonists – Second Review
- h) Testosterone Products – Second Review
- i) Apremilast (Ltezla) – Second Review

13. Miscellaneous

- a) DUR Digest Vol. 27, No. 3 – Initial Review
- b) MedWatch

14. Executive Closed Session

- a) Approval of Minutes
- b) Member Profiles

15. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131

*****Next Meeting June 3, 2015***
Learning Resource Center
3550 Mills Civic Parkway, West Des Moines, IA 50265**